Cannabis Detox Medication Advances to Phase 3 Trials

Cannabis detox is moving toward its first medication. PleoPharma’s experimental drug PP-01 enters a pivotal phase 3 trial for cannabis withdrawal syndrome. It’s funded by the National Institute on Drug Abuse and a Fast Track designation from the FDA according to Psychiatric Times.

PleoPharma designed the oral therapy PP-01 for people with moderate to severe cannabis use disorder who are trying to stop. If approved it would become the first medication approved for cannabis withdrawal in a field where patients currently have no drug options.

Why Medical Detox Matters for Cannabis

Cannabis withdrawal often doesn’t create the physical danger associated with alcohol or benzodiazepine withdrawal. But it can still pull people back toward use because withdrawal symptoms frequently drove patients who wanted to stop using cannabis back to use.

Speaking with Psychiatric Times, Shelli Graham PhD, senior vice president of medical and clinical research at PleoPharma, said it undermined users cessation efforts.

A supervised detox setting or an outpatient plan with clinical check-ins gives a person structure throughout the withdrawal period instead of leaving them to manage the process alone.

How Cannabis Detox Works Without an Approved Medication

Heavy cannabis use suppresses CB1 receptors, which serve as the brain’s primary cannabinoid receptors and disrupts neurotransmitter signaling in the mesolimbic reward pathway. PP01 targets both problems through a dual mechanism designed to address the underlying changes associated with withdrawal.

Earlier phase 1b, 2a and 2b trials showed that PP01 reduced cannabis withdrawal symptoms in adults with moderate to severe cannabis use disorder. The phase 3 program including the CAN004 trial, now seeks to confirm those findings through rigorous evidence based research.

CAN004 enrollment has moved ahead of projections which Graham described as evidence of substantial unmet need. The FDA’s Fast Track designation indicates that the agency considers the condition serious and the drug a candidate for an accelerated development and review process.

The Treatment Gap Behind the Trial

Graham emphasized the people who could benefit from the medication. “There’s so many people who are impacted by cannabis use disorder and cannabis withdrawal with no approved FDA approved medication” she noted.

NIDA awarded PleoPharma a $6.5 million grant in August to advance the phase 3 program, according to the source’s reference list.

Graham said rising rates of cannabis use disorder, particularly among people with moderate and severe conditions, demonstrate the need for pharmacologic support. More people are using heavily. More are attempting to quit, which means unsuccessful attempts can erode motivation to continue pursuing recovery.

Medication and Therapy Work Together

Graham emphasized that PP01 is not a standalone cure. Medication addresses one component of cannabis withdrawal, while behavioral therapy addresses secondary and underlying issues that require continued management throughout recovery.

These approaches work together rather than serving as substitutes for one another other. That combination also reflects the broader role of medical detox for other substances because withdrawal management helps stabilize a person, while therapy relapse prevention planning and support groups provide continued assistance afterward.

Finding Medical Detox

If you or someone you love is trying to stop heavy cannabis use, you do not need to wait for a new medication because treatment options already exist.

Search Detox.com for medically supervised detox and drug detox programs that provides treatment for cannabis dependence. Ask about behavioral therapy options that can help complement withdrawal support.

Never attempt alcohol or benzodiazepine withdrawal without medical supervision. Call 800-996-6135Sponsored to find a medically supervised detox program near you that can help you begin recovery.